Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital transactions.
- Shares Repurchased: 1,500,000 ordinary shares of 25 pence each.
- Transaction Date: June 23, 2011.
- Price Range: Highest price paid was 1,282.5 pence per share; lowest price paid was 1,268.5 pence per share.
- Treasury Shares Held: 499,174,284 shares (representing 8.85% of total issued share capital and 9.71% of total voting rights).
- Shares in Issue: 5,142,212,323 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's issued share capital through the cancellation of 1,500,000 repurchased shares. Consequently, the total number of shares in issue (excluding Treasury shares) stands at 5,142,212,323. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase or subscribe for securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,142,212,323) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (499,174,284) and its impact on voting rights (9.71%).
- Review the specific price range paid for the repurchase (1,268.5 to 1,282.5 pence) to assess capital allocation efficiency.
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.